Redfund Capital Corporation (CSE:LOAN) (Frankfurt: O3X4) (OTC: PNNRF) (Redfund or the “Company”) a merchant bank focused on financing medical cannabis, CBD and hemp companies is pleased to announce the launch of Dr. Klein CBD, and welcomes Dr. Robert Klein as a USA based advisor to the Company.

Dr. Klein CBD is launching a new line of pharma-grade infused CBD nutraceuticals, which include skin topicals and bath products. The Dr. Klein brand has a pain cream, healing stick, face moisturizer, infused serum plus the popular CBD infused bath bombs. The initial rollout will focus on the US chiropractic community and online consumer marketing, and then roll out globally in the fall.


“There are more than 60,000 doctors of chiropractic practicing in the United States. All 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands recognize chiropractic as a health care profession and license the practice.” (American Chiropractic Association)

Dr. Robert Klein was raised in South Brunswick, New Jersey, received his Bachelor of Science in Human Biology and Doctor of Chiropractic degrees from the National College of Chiropractic in Lombard, Illinois. In 1995 Dr. Klein relocated and brought his award winning ways to Boca Raton, Florida. As a dedicated member of the Boca Raton community for over 23 years, Dr. Klein has been fortunate enough to be the official Chiropractor for Florida Atlantic University for 15 years. Dr. Klein has had the privilege of being on the Board of Directors for the Florida Chiropractic Association and has been the Palm Beach County delegate for the last 18 years, plus the past president of the local Palm Beach County Chiropractic Society and Keiser University’s Doctor of Chiropractic program board member, 2018, 2019.

“We are pleased to support Dr. Klein and the launch of the Dr. Klein CBD brand of pharma-grade CBD topicals and infused bathing products. These products will be laboratory tested prior to sales. We look forward to launching the Dr. Klein brand into Europe, South America and into Canada when regulation allows in the fall of 2019. Redfund will have an equity stake in the venture with further  details to be released once definitive agreements are signed with Dr. Klein,” said Meris Kott, CEO.

“Nearly 7 percent of Americans are already using cannabidiol (CBD), placing the potential market opportunity for the much-hyped cannabis compound at $16 billion by 2025, according to a new analysis by Cowen & Co.” (Bloomberg LP)

According to an article written by Aaron Cadena a CBD enthusiast, passionate writer, and editor in chief at www.cbdorigin.com ― the CBD community’s leading digital publication and online knowledge base on May 8, 2019; “There has been a massive growth of awareness and surge in the retail sales of CBD, leading analyst to predict that the CBD market could reach a value of $22 billion by 2022. Research has revealed even more applications of CBD; Hemp-derived CBD was federally legalized under the 2018 Farm Bill. The FDA approved of a CBD-based oral solution called Epidolex; CBD products are now being sold online in stores across the country, including major retailers like 711, Sephora, and Neiman Marcus.”

Update: Jerry Hug announced as an advisor on  February 7, 2019 is no longer an advisor to the Company.

About Redfund Capital

Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development, or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related, healthcare-related target companies.

For further information please visit www.redfundcapital.com

For more information on Redfund Capital contact
Meris Kott CEO 604.484.8989
Or info@redfundcapital.com

Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Click here to connect with Redfund Capital Corporation (CSE:LOAN) for an Investor Presentation. 

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005411/en/

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72301_betterplanta.jpg

Keep reading... Show less